Molecular marker combination for prognosis prediction, prognosis evaluation and / or treatment scheme selection of object and application of molecular marker combination

By using specific gene marker combinations and compound machine learning algorithms, a prognostic prediction model for sepsis is constructed, which solves the inaccuracy of early prediction and treatment plan selection in the prior art, and realizes the use of sepsis patients Accurate prediction of prognosis and optimization of treatment options.

CN118979105APending Publication Date: 2024-11-19CHENGDU CELENOV BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411001324.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art has subjectivity and inaccuracy in the early prediction of sepsis and the selection of treatment options, and cannot effectively predict patients' disease progression and survival rates.

Method used

The molecular marker combination of genes such as ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK and SLC38A1 was used to construct sepsis by combining complex machine learning algorithms. Patient prognosis prediction model, identifying immune-related risk scoring systems through gene expression data and immunotyping.

Benefits of technology

Accurate prediction of the prognosis of sepsis patients is achieved, helping clinicians to formulate personalized treatment plans, improve patients' survival rates, and optimize treatment plans to avoid unnecessary treatment and waste of medical resources.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979105A_ABST
    Figure CN118979105A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of in-vitro diagnosis, and particularly relates to a molecular marker combination for prognosis prediction, prognosis evaluation and / or treatment scheme selection of an object and application of the molecular marker combination. The molecular marker combination comprises one or more of ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK and SLC38A1, and the molecular marker combination comprises one or more of ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, the molecular marker combination composed of the 16 genes provides a new thought for the field of sepsis treatment, and also provides a new direction and possibility for future clinical treatment and disease management.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of in vitro diagnosis, and specifically relates to a molecular marker combination and its use for object prognosis prediction, prognosis assessment and / or treatment regimen selection. Background Art

[0002] In the treatment and management of sepsis, early prediction of patient prognosis is crucial for adopting appropriate treatment strategies. Traditionally, clinicians mainly rely on clinical indicators, medical history, and clinical experience to assess patients' condition and prognosis. However, these methods have certain subjectivity and limitations and cannot accurately predict patients' disease progression and survival rate. In recent years, with the development of biotechnology and information technology, more and more studies have shown that gene expression levels are closely related to the occurrence and development of diseases. The combination of molecular markers based on gene expression data has become an important tool for predicting disease prognosis. By analyzing the patient's gene expression data, key genes related to disease prognosis can be found, and prediction models can be constructed to accurately predict the patient's prognosis. On the other hand, the application of machine learning algorithms has also received widespread attention in the medical field. Composite machine learning algorithms, such as decision trees, support vector machines, and neural networks, can learn and discover hidden patterns and laws from large amounts of data, thereby building prediction models and improving the accuracy and reliability of predictions.

[0003] Therefore, combining gene expression data and composite machine learning algorithms to construct a prognosis prediction model for sepsis patients has important clinical application prospects. This molecular marker-based prognosis prediction method can provide clinicians with more accurate prognosis assessments, help them develop personalized treatment plans, and improve patient treatment outcomes and survival rates. Summary of the invention

[0004] In order to achieve the above technical objectives, the present invention hereby proposes the following technical solutions:

[0005] One of the objects of the present invention is to provide a molecular marker combination for subject prognosis prediction, prognosis assessment and / or treatment regimen selection, which includes one or more of ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK and SLC38A1.

[0006] in,

[0007] The ARL4C (ADP ribosylation factor like GTPase 4C) Gene ID: 10123 (https: / / www.ncbi.nlm.nih.gov / gene / 10123); Uniprot ID: P56559 (https: / / www.uniprot.org / uniprotkb / P56559 / entry);

[0008] The DOCK10 (DOCK10 dedicator of cytokinesis 10) Gene ID: 55619 (https: / / www.uniprot.org / uniprotkb / P56559 / entry); Uniprot ID: Q96BY6 (https: / / www.uniprot.org / uniprotkb / Q96BY6 / entry);

[0009] The FNBP4 (Formin-binding protein 4) Gene ID: 23360 (https: / / www.ncbi.nlm.nih.gov / gene / 23360); Uniprot ID: Q8N3X1 (https: / / www.uniprot.org / uniprotkb / Q8N3X1 / entry);

[0010] The FBXO21 (F-box protein 21) Gene ID: 23014 (https: / / www.ncbi.nlm.nih.gov / gene / 23014); Uniprot ID: O94952 (https: / / www.uniprot.org / uniprotkb / O94952 / entry);

[0011] The CD74 (CD74 molecule) Gene ID: 972 (https: / / www.ncbi.nlm.nih.gov / gene / 972); Uniprot ID: E7EQJ3 (https: / / www.uniprot.org / uniprotkb / E7EQJ3 / entry);

[0012] The said PEPD (peptidase D) Gene ID: 5184 (https: / / www.ncbi.nlm.nih.gov / gene / 5184); Uniprot ID: P12955 (https: / / www.uniprot.org / uniprotkb / P12955 / entry);

[0013] The said DFFA (DNA fragmentation factor subunit alpha) Gene ID: 1676 (https: / / www.ncbi.nlm.nih.gov / gene / 1676); Uniprot ID: O00273 (https: / / www.uniprot.org / uniprotkb / O00273 / entry);

[0014] The said SLC7A6 (solute carrier family 7 member 6) Gene ID: 9057 (https: / / www.ncbi.nlm.nih.gov / gene / 9057); Uniprot ID: Q92536 (https: / / www.uniprot.org / uniprotkb / Q92536 / entry);

[0015] The said FYN (FYN proto-oncogene, Src family tyrosine kinase) Gene ID: 2534 (https: / / www.ncbi.nlm.nih.gov / gene / 2534); Uniprot ID: P06241 (https: / / www.uniprot.org / uniprotkb / P06241 / entry);

[0016] The said MGMT (O-6-methylguanine-DNA methyltransferase) Gene ID: 4255 (https: / / www.ncbi.nlm.nih.gov / gene / 4255); Uniprot ID: P16455 (https: / / www.uniprot.org / uniprotkb / P16455 / entry);

[0017] The RASSF1 (Ras association domain family member 1) Gene ID: 11186 (https: / / www.ncbi.nlm.nih.gov / gene / 11186); Uniprot ID: Q9NS23 (https: / / www.uniprot.org / uniprotkb / Q9NS23 / entry);

[0018] The IMP3 (IMP3U3 small nucleolar ribonucleoprotein 3) Gene ID: 55272 (https: / / www.ncbi.nlm.nih.gov / gene / 55272); Uniprot ID: Q9NV31 (https: / / www.uniprot.org / uniprotkb / Q9NV31 / entry);

[0019] The DDX18 (DEAD-box helicase 18) Gene ID: 8886 (https: / / www.ncbi.nlm.nih.gov / gene / 8886); Uniprot ID: Q9NVP1 (https: / / www.uniprot.org / uniprotkb / Q9NVP1 / entry);

[0020] The TTC19 (tetratricopeptide repeat domain 19) Gene ID: 54902 (https: / / www.ncbi.nlm.nih.gov / gene / 54902); Uniprot ID: Q6DKK2 (https: / / www.uniprot.org / uniprotkb / Q6DKK2 / entry);

[0021] The AHNAK (AHNAK nucleoprotein) Gene ID: 79026 (https: / / www.ncbi.nlm.nih.gov / gene / 79026); Uniprot ID: Q09666 (https: / / www.uniprot.org / uniprotkb / Q09666 / entry);

[0022] The SLC38A1 (solute carrier family 38 member 1) Gene ID: 81539; UniprotID: Q9H2H9 (https: / / www.uniprot.org / uniprotkb / Q9H2H9 / entry).

[0023] In some preferred embodiments, the molecular marker combination consists of ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK and SLC38A1.

[0024] In some embodiments, the subject suffers from a sepsis-related disease.

[0025] In some embodiments, the subject also suffers from another disease other than sepsis-related disease.

[0026] In some embodiments, the subject has been previously treated for a sepsis-related disease.

[0027] In some preferred embodiments, the sepsis-related disease includes sepsis, severe sepsis or septic shock.

[0028] In some preferred embodiments, the sepsis-related disease is sepsis.

[0029] A second object of the present invention is to provide use of any of the aforementioned molecular marker combinations in the preparation of a product for subject prognosis prediction, prognosis assessment and / or treatment regimen selection.

[0030] In some embodiments, the product is used to test a sample from a subject to achieve prognosis prediction, prognosis assessment and / or treatment regimen selection.

[0031] In some embodiments, the sample includes, but is not limited to: blood, tissue, body fluid, metabolites and / or excreta.

[0032] In some preferred embodiments, the sample is selected from whole blood, serum, plasma, lymph, cerebrospinal fluid, pleural effusion, gastric juice, ascites, saliva, throat swab, feces and urine.

[0033] In some embodiments, the subject suffers from a sepsis-related disease.

[0034] In some embodiments, the subject also suffers from another disease other than sepsis-related disease.

[0035] In some embodiments, the subject has been previously treated for a sepsis-related disease.

[0036] In some preferred embodiments, the treatment of sepsis-related diseases includes drug therapy, adjuvant therapy and / or medical device therapy.

[0037] In some preferred embodiments, the sepsis-related disease includes sepsis, severe sepsis or septic shock.

[0038] In some preferred embodiments, the sepsis-related disease is sepsis.

[0039] In some embodiments, the product comprises a substance that is specific for the molecular marker composition or is capable of specifically recognizing the molecular marker composition.

[0040] In some embodiments, the substances include reagents, kits, and / or detection devices.

[0041] In some preferred embodiments, the substance comprises or is selected from at least one of the following:

[0042] Immunological detection reagents (such as ELISA reagents), molecular biology detection reagents (such as QPCR reagents, ddPCR reagents), flow cytometer detection reagents, immunological detection kits (such as ELISA kits), molecular biology detection kits (such as QPCR kits, ddPCR kits), biochip reagents (such as protein chips), biochip kits.

[0043] In some preferred embodiments, the substance comprises or is selected from at least one of the following:

[0044] Primers, probes, antibodies, biochips or small molecule compounds.

[0045] In some preferred embodiments, the substance carries or is conjugated to a detectable label.

[0046] In some preferred embodiments, the detectable label includes, but is not limited to: biotin, streptavidin, an enzyme or a catalytically active fragment thereof, a radionuclide, a nanoparticle, a paramagnetic metal ion, or a fluorescent, phosphorescent, or chemiluminescent molecule.

[0047] In some preferred embodiments, the detection device is compatible with the detection method, such as a detection device for digital PCR, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), real-time quantitative reverse transcription PCR, chemiluminescent immunoassay (CLIA), biochip detection, Southern blotting, Northern blotting in situ hybridization, immunofluorescence, immunohistochemistry, or Northern blotting or in situ hybridization.

[0048] A third object of the present invention is to provide a product for predicting the prognosis, evaluating the prognosis and / or selecting a treatment regimen for a subject, wherein the product comprises a substance that is specific for any of the aforementioned molecular marker combinations or that can specifically recognize any of the aforementioned molecular marker combinations.

[0049] In some embodiments, the subject suffers from a sepsis-related disease.

[0050] In some embodiments, the subject also suffers from another disease other than sepsis-related disease.

[0051] In some embodiments, the subject has been previously treated for a sepsis-related disease.

[0052] In some preferred embodiments, the treatment of sepsis-related diseases includes drug therapy, adjuvant therapy and / or medical device therapy.

[0053] In some preferred embodiments, the sepsis-related disease includes sepsis, severe sepsis or septic shock.

[0054] In some preferred embodiments, the sepsis-related disease is sepsis.

[0055] In some embodiments, the substances include reagents, kits, and / or detection devices.

[0056] In some preferred embodiments, the substance comprises or is selected from at least one of the following:

[0057] Sequencing reagents (e.g., RNA sequencing reagents), immunological detection reagents (e.g., ELISA reagents), molecular biology detection reagents (e.g., QPCR reagents, ddPCR reagents), flow cytometer detection reagents, immunological detection kits (e.g., ELISA kits), molecular biology detection kits (e.g., QPCR kits, ddPCR kits), sequencing kits (e.g., RNA sequencing kits), biochip reagents (e.g., protein chips), and biochip kits.

[0058] In some preferred embodiments, the substance comprises or is selected from at least one of the following:

[0059] Primers, probes, antibodies, biochips or small molecule compounds.

[0060] In some preferred embodiments, the substance carries or is conjugated to a detectable label.

[0061] In some preferred embodiments, the detectable label includes, but is not limited to: biotin, streptavidin, an enzyme or a catalytically active fragment thereof, a radionuclide, a nanoparticle, a paramagnetic metal ion, or a fluorescent, phosphorescent, or chemiluminescent molecule.

[0062] In some preferred embodiments, the detection device is compatible with the detection method, such as a detection device for digital PCR, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), microarray technology, real-time quantitative reverse transcription PCR, chemiluminescent immunoassay (CLIA), biochip detection, Southern blotting, Northern blotting in situ hybridization, immunofluorescence, immunohistochemistry, RNA sequencing, Northern blotting or RNA in situ hybridization.

[0063] A fourth object of the present invention is to provide use of any of the aforementioned molecular marker combinations or products in subject prognosis prediction, prognosis assessment and / or treatment regimen selection.

[0064] In some embodiments, the subject suffers from a sepsis-related disease.

[0065] In some embodiments, the subject also suffers from another disease other than sepsis-related disease.

[0066] In some embodiments, the subject has been previously treated for a sepsis-related disease.

[0067] In some preferred embodiments, the treatment of sepsis-related diseases includes drug therapy, adjuvant therapy and / or medical device therapy.

[0068] In some preferred embodiments, the sepsis-related disease includes sepsis, severe sepsis or septic shock.

[0069] In some preferred embodiments, the sepsis-related disease is sepsis.

[0070] A fifth object of the present invention is to provide a method for predicting prognosis, evaluating prognosis and / or selecting a treatment regimen for a subject, the method comprising the following steps:

[0071] (1) collecting and / or processing a sample of the subject so that the sample is detectable at the molecular level;

[0072] (2) detecting the molecular level of any of the aforementioned molecular marker combinations in the subject sample described in step (1);

[0073] (3) Predicting the prognosis of the subject based on the molecular level analysis data described in step (2).

[0074] In some embodiments, the molecular level includes gene (expression) level and / or protein (expression) level.

[0075] In some embodiments, the sample includes, but is not limited to: blood, tissue, body fluid, metabolites and / or excreta.

[0076] In some preferred embodiments, the sample is selected from whole blood, serum, plasma, lymph, cerebrospinal fluid, pleural effusion, gastric juice, ascites, saliva, throat swab, feces and urine.

[0077] In some embodiments, the subject suffers from a sepsis-related disease.

[0078] In some embodiments, the subject also suffers from another disease other than sepsis-related disease.

[0079] In some embodiments, the subject has been previously treated for a sepsis-related disease.

[0080] In some preferred embodiments, the treatment of sepsis-related diseases includes drug therapy, adjuvant therapy and / or medical device therapy.

[0081] In some preferred embodiments, the sepsis-related disease includes sepsis, severe sepsis or septic shock.

[0082] In some preferred embodiments, the sepsis-related disease is sepsis.

[0083] A sixth object of the present invention is to provide use of any of the aforementioned molecular compositions in establishing a prognostic model for subject prognosis prediction, prognosis assessment and / or treatment regimen selection.

[0084] In some embodiments, the prognostic model is a prognostic model based on immunophenotyping and a composite machine learning algorithm.

[0085] In some preferred embodiments, the composite machine learning algorithm includes, but is not limited to: decision tree, support vector machine, neural network, etc.

[0086] In some embodiments, the prognostic model is stored in a computer-readable storage medium.

[0087] In some embodiments, the computer storage medium stores a computer program.

[0088] In some embodiments, the computer storage medium is executable on a computer device.

[0089] A seventh object of the present invention is to provide a system for predicting prognosis, evaluating prognosis and / or selecting a treatment regimen for a subject, the system comprising:

[0090] 1) a data processing module, receiving and / or processing data at the molecular level comprising any of the aforementioned molecular marker combinations in a subject;

[0091] 2) An analysis and calculation module is used to predict the prognosis of the subject based on the data obtained in step 1).

[0092] In some embodiments, step 2) further comprises the step of establishing a prediction model based on the data obtained in step 1).

[0093] In some embodiments, the system further comprises a data collection module for collecting a sample from the subject, wherein the sample comprises data at the molecular level of any of the aforementioned molecular marker compositions.

[0094] In some embodiments, the prognostic model is a prognostic model based on immunophenotyping and a composite machine learning algorithm.

[0095] In some preferred embodiments, the composite machine learning algorithm includes, but is not limited to: decision tree, support vector machine, neural network, etc.

[0096] In some embodiments, the subject suffers from a sepsis-related disease.

[0097] In some embodiments, the subject also suffers from another disease other than sepsis-related disease.

[0098] In some embodiments, the subject has been previously treated for a sepsis-related disease.

[0099] In some preferred embodiments, the treatment of sepsis-related diseases includes drug therapy, adjuvant therapy and / or medical device therapy.

[0100] In some preferred embodiments, the sepsis-related disease includes sepsis, severe sepsis or septic shock.

[0101] In some preferred embodiments, the sepsis-related disease is sepsis.

[0102] In some embodiments, the molecular level includes gene (expression) level and / or protein (expression) level.

[0103] An eighth object of the present invention is to provide a computer-readable storage medium comprising a computer program, which, when executed, runs any of the aforementioned systems to implement the functions of any of the aforementioned systems.

[0104] The ninth object of the present invention is to provide a computer device comprising a memory and a processor, wherein the memory stores a computer program, and the processor is used to execute the computer program to implement the functions of any of the aforementioned systems.

[0105] The present invention divides sepsis patients into two immune subtypes: low-risk type I and high-risk type II by using 28 immune cell features annotated by single sample gene set enrichment analysis (ssGSEA) and consensus clustering analysis. The validated transcriptome dataset invented by the present invention divides sepsis patients into two immune subtypes: low-risk type I and high-risk type II. The biomarkers related to immune subtypes were identified by weighted gene co-expression network (WGCNA) analysis combined with consensus clustering, and it was found that the genes in the MEdarked module were the core genes of sepsis immune subtypes. A prognostic prediction model for sepsis was constructed by 10 machine learning algorithms and 101 composite machine learning algorithms: an immune-related risk scoring system. The model consists of 16 genes: ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK and SLC38A1. In the invention data set, the model's area under the receiver operating curve (ROC) curve (AUC) values ​​for diagnosing sepsis at 7, 14 and 28 days of survival reached 0.85, 0.86 and 0.87, respectively, and can accurately predict the prognosis of sepsis patients. By analyzing the transcriptome data of 59 sepsis patients in the Department of Critical Care Medicine, West China Hospital, Sichuan University, using this model, the area under the ROC curve (AUC) values ​​at 7, 14 and 28 days reached 0.78, 0.84 and 0.83, respectively, and the external validity of the model was verified.

[0106] The prognosis prediction model provided by the present invention can timely and accurately predict the prognosis of sepsis patients, helping clinicians optimize treatment plans and thus improve the survival rate of patients. It can also avoid unnecessary treatment and waste of medical resources, thereby reducing medical costs and improving the efficiency of medical resource utilization. In addition, this group of 16 gene molecular marker combinations provides new ideas for the field of sepsis treatment, and also provides new directions and possibilities for future clinical treatment and disease management. BRIEF DESCRIPTION OF THE DRAWINGS

[0107] Figure 1 The use of heatmaps to demonstrate the differences in the two immune phenotypes is shown.

[0108] Figure 2 The use of box plots to demonstrate the differences in the two immune phenotypes is shown.

[0109] Figure 3Shown are the immune scores and ESTIMATE scores demonstrating two immune phenotypes.

[0110] Figure 4 The Kaplan-Meier survival curve was used to analyze the prognostic value of the 16-gene IRRS typing system for sepsis patients in the GSE65682 dataset.

[0111] Figure 5 The use of ROC curves to validate the robustness of IRRS is shown.

[0112] Figure 6 The results of ROC analysis of IRRS in the GSE65682 dataset are shown.

[0113] Figure 7 The results of ROC analysis of IRRS in the GSE63042 dataset are shown.

[0114] Figure 8 The results of ROC analysis of IRRS in the EMTAB4451 dataset are shown.

[0115] Fig. 9 The results of ROC analysis of IRRS in the EMTAB5273 dataset are shown.

[0116] Fig.10 The results of ROC analysis of IRRS in the EMTAB5274 dataset are shown.

[0117] Fig.11 The results of ROC analysis of IRRS in the EMTAB7581 dataset are shown.

[0118] Fig.12 Shown is the C-index comparison of IRRS with clinicopathological factors in all data sets.

[0119] Fig.13 The use of KM curves to determine the prognostic value of IRRS is shown.

[0120] Fig.14 The use of ROC curves to validate the robustness of IRRS is shown.

[0121] Fig.15 Comparison of the IRRS with the C-index of clinicopathological factors is shown.

[0122] Fig.16 The results of multivariate Cox regression analysis are shown for the relationship between IRRS and multiple clinical factors.

[0123] Fig.17Heat map analysis of the differential expression of 16 genes in different immunophenotype groups is shown.

[0124] Fig.18 Violin plots showing the differences in expression of SLC7A5, FNBP4, SLC38A1, and TTC19 in different immunophenotype groups are shown.

[0125] Fig.19 The enrichment analysis revealed pathway changes between different scoring groups.

[0126] Fig. 20 Enrichment analysis revealed changes in metabolic reprogramming between different scoring groups. DETAILED DESCRIPTION

[0127] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0128] The present invention may be implemented in other specific forms without departing from the basic attributes of the present invention. It should be understood that, without conflict, any and all embodiments of the present invention may be combined with the technical features in any other embodiment or multiple other embodiments to obtain other embodiments. The present invention includes other embodiments obtained by such combination.

[0129] All publications and patents mentioned in the present invention are hereby incorporated into the present invention by reference in their entirety. If the purposes or terms used in any publications and patents incorporated by reference conflict with the purposes or terms used in the present invention, then the purposes and terms of the present invention shall prevail.

[0130] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0131] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.

[0132] Unless the context clearly dictates otherwise, the expressions "a", "an" and "an" as used herein include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.

[0133] As shown in the present invention, the term "about" means a range of ±20% of the value thereafter. In some embodiments, the term "about" means a range of ±10% of the value thereafter. In some embodiments, the term "about" means a range of ±5% of the value thereafter.

[0134] The numerical range used in the present invention should be understood to have listed all the numbers within the range. For example, the range of 1 to 20 should be understood to include any number, number combination or subrange from the following group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0135] As shown in the present invention, the term "comprises" or "comprising" means "including but not limited to". The term is intended to be open-ended to specify the presence of any stated features, elements, integers, steps, or components, but does not exclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Therefore, the term "comprising" includes the more restrictive terms "consisting of" and "consisting essentially of". In one embodiment, the term "comprising" used throughout the invention, especially in the claims, may be replaced by the term "consisting of".

[0136] As used herein, the terms "optional", "either", "any", or "any" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur. As used herein, "a" and "an" are used herein to refer to one or more than one of the grammatical objects.

[0137] As shown in the present invention, "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.

[0138] The term "sepsis-related disease" used in the present invention refers to a class of diseases of life-threatening organ dysfunction caused by a disordered host response to infection, including, but not limited to, sepsis, septic shock, and severe sepsis. In some preferred embodiments, the sepsis-related disease is sepsis. The specific definition and diagnostic criteria of sepsis can be found in Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8): 801-810. doi: 10.1001 / jama.2016.0287.

[0139] The terms "reagent", "detection reagent" or "reagent for detecting the level of a molecular marker combination molecule" used herein are used interchangeably, and all refer to reagents that are specific for the molecules of the molecular marker combination of the present invention, and can be used to directly or indirectly detect the presence and / or content of the level of the molecular marker combination of the present invention. These detection substances can detect the molecular marker combination of the present invention at the gene level or protein level. According to the sequence of the molecular marker combination molecule of the present invention, a person of ordinary skill in the art can prepare or obtain a reagent that is specific for the molecular marker combination molecule of the present invention based on conventional means. For example, the detection reagents available in this application include, but are not limited to: antibodies (preferably monoclonal antibodies), probes, gene chips, PCR primers, gRNA, etc. that have detection specificity for the molecules of the molecular marker combination of the present invention. In addition, in order to facilitate detection, the detection reagent of the present invention may also carry a detectable label, and the detectable label is not limited to: radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (such as biotin or haptens), etc. The detection reagent of the present invention may be present in a solution, fixed on a carrier (such as a substrate, an adsorbent), or in other conventional forms in the art, as long as the form of existence is suitable for detecting the combination of molecular markers of the present invention in a biological sample. For example, when the detection reagent of the present invention is a nucleotide probe, it can be present in the form of a biochip (or "microarray").

[0140] The terms "product" or "test product" used herein are used interchangeably, meaning a combination of substances, reagents or their combined use, auxiliary use, etc. that contain detection, specific for the molecular marker combination of the present invention. According to the needs of the detection method used, the detection substance of the appropriate molecular marker combination of the present invention can be selected and made into a product suitable for the detection method used, such as a kit. A person of ordinary skill in the art can adjust and change the detection method and the reagents contained in the product according to actual conditions and needs. The product of the present invention may also include other reagents clinically used for early diagnosis of sepsis-related diseases in subjects, risk assessment, immune status assessment, prognosis prediction (or assessment, judgment) and / or treatment regimen selection, to assist or verify the results obtained by detecting the molecular marker combination of the present invention. A person of ordinary skill in the art can make routine selections according to specific needs.

[0141] The term "prognosis prediction" or "prognosis assessment" as used herein refers to the prognostic judgment of the course and / or outcome of the subject, or the evaluation and judgment or monitoring of the therapeutic effect of the therapeutic agent. In some instances, the subject suffers from a sepsis-related disease. In some instances, the subject also suffers from other diseases other than sepsis-related diseases. In some instances, the subject has previously received treatment for a sepsis-related disease. In some preferred instances, the sepsis-related disease includes sepsis, severe sepsis or septic shock. In some more preferred instances, the sepsis-related disease is sepsis.

[0142] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiment. If the specific conditions are not specified in the embodiment, it is carried out according to the conditions of normal conditions or manufacturer's suggestion. If the manufacturer is not specified in all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concept of the present invention. Such structures and technologies are also described in the publication of many publications.

[0143] Example 1: Prognosis prediction model construction

[0144] The present invention analyzes 479 sepsis patients with clinical prognostic information from a validated transcriptome dataset invented by single sample gene set enrichment analysis (ssGSEA) using 28 immune cell features annotated by consensus cluster analysis - sequencing dataset GSE65682 of the public database GEO database (https: / / www.ncbi.nlm.nih.gov / geo / query / acc.cgi?acc=GSE65682), and divides sepsis patients into two immunophenotypes: low-risk type I and high-risk type II ( Figure 1-Figure 3 ).

[0145] We identified biomarkers related to immune subtypes by weighted gene co-expression network analysis (WGCNA) combined with consensus clustering, and found that genes in the MEdarked module were core genes of the immune subtypes of sepsis.

[0146] In order to obtain a robust risk assessment system, the present invention trained immune-related genes that met the criteria in a model containing 101 composite machine learning algorithms, and all six data sets (GSE65682, GSE63042, EMTAB-4451, EMTAB5273, EMTAB5274, EMTAB7581) participated in this training. The present invention used the machine learning model that produced the highest average C index value as the best method for constructing a risk score. The results showed that the Stepcox (backwork) + GBM screening method had the highest average c-index value, so the present invention used this algorithm as the best algorithm for gene screening, and finally screened out 16 genes and incorporated them into the final model-immune-related risk score IRRS system. The system consists of 16 genes: ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK and SLC38A1.

[0147] like Figure 4 and Figure 5 As shown in the GSE65682 data set, high-risk patients have a poor prognosis. In addition, the AUC values ​​of the ROC curves of patients at 7 days, 14 days and 28 days are 0.85, 0.86 and 0.87, respectively. In other data sets, the 28-day survival of patients in the high-risk group is shorter, which further confirms the reliability of the model of the present invention.

[0148] Example 2: Robustness verification of IRRS system

[0149] like Figure 6-Figure 11 As shown, the prognostic performance of the IRRS score was very stable in all datasets.

[0150] We further integrated additional clinical information from the six datasets and compared the C-index values ​​of IRRS and other clinical factors. In all datasets, the C-index values ​​of IRRS exceeded those of other clinical factors and could be used as an independent prognostic indicator. We further compared the prognostic performance by incorporating IRRS scores and other clinical factors into multivariate regression analysis, showing that the independent prognostic significance of IRRS for 28-day survival was very stable in all datasets ( Fig.12 ).

[0151] Example 3: Clinical Prospective Validation of the IRRS System

[0152] The present invention collected peripheral blood from 59 sepsis patients (included according to the Sepsis-3 standard) in the Department of Critical Care Medicine, West China Hospital, Sichuan University, and performed whole-genome transcriptome sequencing to conduct clinical prospective verification of the prognostic diagnostic efficacy of sepsis.

[0153] The present invention further validated the IRRS score in the West China cohort. First, whole transcriptome sequencing was performed on 59 sepsis patients, and the gene expression information of the patients was obtained. The IRRS score of each patient was calculated by the previous algorithm.

[0154] The results showed that in the Huaxi cohort, patients with high scores showed worse prognosis ( Fig.13 ). In addition, the IRRS score showed satisfactory predictive stability in our cohort, with AUCs of 0.78, 0.84, and 0.83 at 7, 14, and 28 days, respectively ( Fig.14 ). Patients in the low-risk group showed a relatively higher ratio of lymphocytes to monocytes. Patients in the high-risk group also had a higher ICU mortality rate.

[0155] The IRRS score was further compared with other clinical factors by multivariate cox regression. The results showed that the IRRS score was an independent risk factor for sepsis and had a higher C index than other clinical risk factors ( Fig.15 and Fig.16 ).

[0156] We further evaluated the expression of these key IRRS genes (16 genes) in different risk groups and found that most genes were expressed at lower levels in the high-risk group ( Fig.17 ). In particular, SLC7A5, FNBP4, SLC38A1, and TTC19 showed significant expression differences ( Fig.18 ).

[0157] The present invention used six immune annotation algorithms to explore the correlation between IRRS scores and immune infiltration. The results showed that the degree of infiltration of most immune cells was negatively correlated with the IRRS score. The analysis further verified the changes in these immune and metabolism-related signals, including "cytokine activity", "cell activation involved in immune response", "amino acid biosynthesis" and "NF-kappaB signaling pathway". The results showed that several chemokines including CCR2, CCR3, CCR5, CXCR5, and CCL5 changed, while interleukins such as IL5RA, IL15, IL10, IL32 and their related receptors were significantly different between the two groups ( Fig.19 and Fig. 20 ).

[0158] The changes and differences in glucose metabolism, lipid metabolism, and protein metabolism between the high-risk and low-risk groups were further analyzed. In the lipid metabolism analysis, there were significant differences in pathways such as lipid biosynthesis process, lipid transport, and membrane lipid metabolism. In the protein metabolism analysis, pathways of protein localization, signal transduction, and hydroxylation were changed. In the glucose metabolism analysis, reprogramming occurred in glucagon secretion, glucose homeostasis, and other aspects ( Fig. 20 ).

[0159] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A molecular marker combination for predicting prognosis, evaluating prognosis and / or selecting a treatment regimen for a subject, characterized in that: It includes one or more of ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK, and SLC38A1; Preferably, the molecular marker combination consists of: ARL4C, DOCK10, FNBP4, FBXO21, CD74, PEPD, DFFA, SLC7A6, FYN, MGMT, RASSF1, IMP3, DDX18, TTC19, AHNAK and SLC38A1.

2. The molecular marker combination according to claim 1, characterized in that: The subject suffers from a sepsis-related disease; and / or The subject also suffers from other diseases other than sepsis-related diseases; and / or The subject has been previously treated for sepsis-related diseases; Preferably, the sepsis-related disease includes sepsis, severe sepsis or septic shock; More preferably, the sepsis-related disease is sepsis.

3. Use of the molecular marker combination according to any one of claims 1 to 2 in the preparation of a product for subject prognosis prediction, prognosis assessment and / or treatment regimen selection; Preferably, the subject suffers from a sepsis-related disease; and / or The subject also suffers from other diseases other than sepsis-related diseases; and / or The subject has been previously treated for sepsis-related diseases; More preferably, the sepsis-related disease includes sepsis, severe sepsis or septic shock; Most preferably, the sepsis-related disease is sepsis; Preferably, the product is used to detect a sample from a subject to achieve prognosis prediction, prognosis assessment and / or treatment regimen selection; Preferably, the sample comprises blood, tissue, body fluid, metabolites and / or excreta; More preferably, the sample is selected from the group consisting of whole blood, serum, plasma, lymph, cerebrospinal fluid, pleural effusion, gastric juice, ascites, saliva, throat swab, feces and urine.

4. The use according to claim 3, characterized in that: The product comprises a substance that is specific to the molecular marker composition or can specifically recognize the molecular marker composition; Preferably, the substance comprises a reagent, a kit and / or a detection device.

5. A product for predicting prognosis, evaluating prognosis and / or selecting treatment options for a subject, characterized in that: The product comprises a substance that is specific to the molecular marker composition described in any one of claims 1-2 or that can specifically identify the molecular marker composition described in any one of claims 1-2.

6. The product according to claim 5, characterized in that The subject suffers from a sepsis-related disease; and / or The subject also suffers from other diseases other than sepsis-related diseases; and / or The subject has been previously treated for sepsis-related diseases; Preferably, the sepsis-related disease includes sepsis, severe sepsis or septic shock; More preferably, the sepsis-related disease is sepsis.

7. The product according to claim 5 or 6, characterized in that The substances include reagents, kits and / or detection equipment; Preferably, the substance comprises or is selected from at least one of the following: Sequencing reagents, immunology detection reagents, molecular biology detection reagents, flow cytometry detection reagents, immunology detection kits, molecular biology detection kits, sequencing kits, biochip reagents and biochip kits; Preferably, the substance comprises or is selected from at least one of the following: Primers, probes, antibodies, biochips or small molecule compounds; Preferably, the substance carries or is conjugated with a detectable label; More preferably, the detectable label comprises: biotin, streptavidin, an enzyme or a catalytically active fragment thereof, a radionuclide, a nanoparticle, a paramagnetic metal ion, or a fluorescent, phosphorescent, or chemiluminescent molecule.

8. A system for predicting prognosis, evaluating prognosis and / or selecting treatment options for a subject, characterized in that: The system comprises: 1) A data processing module, receiving and / or processing molecular level data containing any combination of molecular markers in claims 1-2 in an object; 2) an analysis and calculation module, predicting the prognosis of the subject according to the data obtained in step 1); Preferably, the system further comprises a data collection module, which is used to collect a sample from the subject, wherein the sample comprises molecular-level data of the molecular marker composition according to any one of claims 1 to 2; Preferably, the step 2) further comprises the step of establishing a prediction model based on the data obtained in step 1); Preferably, the molecular level includes gene level and / or protein level; Preferably, the subject suffers from a sepsis-related disease; and / or The subject also suffers from other diseases other than sepsis-related diseases; and / or The subject has been previously treated for sepsis-related diseases; More preferably, the sepsis-related disease includes sepsis, severe sepsis or septic shock; Most preferably, the sepsis-related disease is sepsis.

9. A computer-readable storage medium comprising a computer program, characterized in that: When the computer program is executed, the system according to claim 8 is operated to realize the functions of the system.

10. A computer device comprising a memory and a processor, wherein the memory stores a computer program, characterized in that: The processor is configured to execute the computer program to implement the functions of the system according to claim 8.